Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Fig. 2

Relative risk of each individual MACE component as a function of CV risk. Hazard ratios for treatment effect (semaglutide vs comparators) across all SUSTAIN and PIONEER trials analyzed. Hazard ratios (semaglutide vs comparators) and 95% CIs estimated using a stratified Cox proportional hazards model including effects of treatment, CV risk score and interaction between both. The x-axis shows the CV risk score derived from subjects’ baseline characteristics in the semaglutide trials. Data on graph cut off at the 5th and 95th percentile of the whole dataset. Hazard ratio value of 1.00 is indicated by a horizontal dashed line. CI confidence interval, CV cardiovascular, HR hazard ratio, MACE major adverse cardiovascular events, MI myocardial infarction

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840